Evidence map›Paper›PMID 36711505›Full record

ArticlebioRxiv : the preprint server for biology2023

Generation of human alveolar epithelial type I cells from pluripotent stem cells.

Claire L Burgess, Jessie Huang, Pushpinder Bawa, Konstantinos-Dionysios Alysandratos, Kasey Minakin, Michael P Morley, Apoorva Babu, Carlos Villacorta-Martin, Anne Hinds, Bibek R Thapa and 5 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 15 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Claire L BurgessCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Jessie HuangCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Pushpinder BawaCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Konstantinos-Dionysios AlysandratosCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Kasey MinakinCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Michael P MorleyPenn-CHOP Lung Biology Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Apoorva BabuPenn-CHOP Lung Biology Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Carlos Villacorta-MartinCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Anne HindsThe Pulmonary Center and Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
Bibek R ThapaCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Feiya WangCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Adeline M MatschulatDepartment of Biochemistry, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA.
Edward E MorriseyPenn-CHOP Lung Biology Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Xaralabos VarelasDepartment of Biochemistry, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 02118, USA.
Darrell N KottonCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA 02118, USA.
Boston University · USUniversity of Pennsylvania · US

Funding

Project-005UL1TR001430 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BAIR-MERRITT, MEGAN H, CENTER, DAVID M. · 2015 to 2024
$52.3M
BIOLOGY OF THE LUNG--MULTIDISCIPLINARY PROGRAMT32HL007035 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Darrell N. Kotton, JOSEPH P MIZGERD · 1985 to 2026
$24.3M
Editing Alveolar Progenitor Cells for Correction of Monogenic DiseaseU01HL134745 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI KOTTON, DARRELL N., MORRISEY, EDWARD E · 2016 to 2022
$8.3M
Epithelial stem/progenitor cells as repair agents in diffuse alveolar damageU01HL134766 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHAPMAN, HAROLD A, KOTTON, DARRELL N. · 2016 to 2022
$8.1M
Derivation of Transplantable Lung Epithelial Progenitors from iPS CellsR01HL095993 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Darrell N. Kotton · 2009 to 2026
$7.5M
Defining epithelial polarity cues that direct cell fateR01HL124392 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI VARELAS, XARALABOS · 2014 to 2024
$4.5M
A National iPS Cell Network with Deep Phenotyping for Translational ResearchU01TR001810 · NCATS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GILAD, YOAV, KOTTON, DARRELL N. · 2016 to 2020
$4.4M
NATIONAL BIOREPOSITORY OF LUNG DISEASE-SPECIFIC HUMAN INDUCED PLURIPOTENT STEM CELLS:THE PURPOSE OF THIS RESOURCE IS TO BUILD AND SUPPORT A CRITICAL75N92020C00005 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI N/A, N/A · 2021 to 2024
$2.6M
Developing a patient-specific organoid model of pulmonary fibrosis using iPSCsU01HL152976 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOTTON, DARRELL N. · 2021 to 2024
$2.5M
Generation of human alveolar epithelial type I cells from pluripotent stem cellsF31HL158193 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BURGESS, CLAIRE · 2021 to 2022
$93k
NCATS NIH HHS U01 TR001810NCATS NIH HHS UL1 TR001430NHLBI NIH HHS 75N92020C00005NHLBI NIH HHS F31 HL158193NHLBI NIH HHS R01 HL095993NHLBI NIH HHS R01 HL124392NHLBI NIH HHS T32 HL007035NHLBI NIH HHS U01 HL134745NHLBI NIH HHS U01 HL134766NHLBI NIH HHS U01 HL152976
6 · The paper itself

Abstract

In the distal lung, alveolar epithelial type I cells (AT1s) comprise the vast majority of alveolar surface area and are uniquely flattened to allow the diffusion of oxygen into the capillaries. This structure along with a quiescent, terminally differentiated phenotype has made AT1s particularly challenging to isolate or maintain in cell culture. As a result, there is a lack of established models for the study of human AT1 biology, and in contrast to alveolar epithelial type II cells (AT2s), little is known about the mechanisms regulating their differentiation. Here we engineer a human in vitro AT1 model system through the directed differentiation of induced pluripotent stem cells (iPSC). We first define the global transcriptomes of primary adult human AT1s, suggesting gene-set benchmarks and pathways, such as Hippo-LATS-YAP/TAZ signaling, that are enriched in these cells. Next, we generate iPSC-derived AT2s (iAT2s) and find that activating nuclear YAP signaling is sufficient to promote a broad transcriptomic shift from AT2 to AT1 gene programs. The resulting cells express a molecular, morphologic, and functional phenotype reminiscent of human AT1 cells, including the capacity to form a flat epithelial barrier which produces characteristic extracellular matrix molecules and secreted ligands. Our results indicate a role for Hippo-LATS-YAP signaling in the differentiation of human AT1s and demonstrate the generation of viable AT1-like cells from iAT2s, providing an in vitro model of human alveolar epithelial differentiation and a potential source of human AT1s that until now have been challenging to viably obtain from patients.

Identifiers

PMID36711505
PMCPMC9882278
OpenAlexW4317653932

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.